Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor.

Autor: Fu Y; College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA; Genentech, Inc, South San Francisco, CA, USA., Saraswat AL; College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA., Monpara J; University of Sciences, Philadelphia, PA, USA., Patel K; College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: patelk2@stjohns.edu.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2022 Apr; Vol. 27 (4), pp. 1132-1141. Date of Electronic Publication: 2021 Nov 22.
DOI: 10.1016/j.drudis.2021.11.015
Abstrakt: Owing to the indispensable role of nanotechnology in cancer therapy, it is imperative to comprehend every aspect limiting its therapeutic potential. Several preclinical reports have demonstrated the enhanced permeability and retention (EPR)-mediated preferential tumor uptake of nanoparticles. However, the therapeutic outcome of nanotherapeutics is severely compromised by heterogeneous drug distribution and insufficient penetration of nanomedicine in a solid tumor owing to the dense tumor extracellular matrix (ECM). Herein, we elaborate on various preclinically investigated tumor stromal disrupting strategies, which we call 'cannons', to compromise the impenetrable 'fortress-like' solid tumor microenvironment. We have described and summarized major approaches to enhance the penetration of a 'nano-arsenal' in solid tumors. ECM remodeling strategies could be very beneficial in enhancing the therapeutic efficacy of monoclonal antibodies and translational nanomedicine.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: